Merck Needs Biotech Startups More Than Ever

Sarah Lacy

It’s day two at the JP Morgan Healthcare conference and the morning started with big pharma presentations. The most anticipated seemed to be Merck & Co. Inc., still reeling from the Vioxx recall.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.